According MarketsandMarkets Research – The Cell Signaling Market is expected to reach $3.51 billion, at a CAGR of 6.8%
The term “cell signaling” is used to define the complex interactive system of signals that regulates and mediate various cellular responses in the human body.
Cell signaling is used to study signaling pathways of cells in drug discovery and therapeutic development, to distinguish drug resistance patterns in cancerous cells. It also identifies the major signaling pathways impacted by specific drug treatments. Cell signaling pathways—also called signal transduction pathways—act as connecting links between environmental stimuli and the corresponding cellular response. These signaling pathways mainly consist of proteins that can interact, move to specific locations, or be modified.
Major Market Drivers:
- Rising Incidence of Chronic Diseases
- Availability of Funding for Cell-Based Research
- Technological Advancements in Cell-Based Research Instruments
- Growth of End-Use Industries
Availability of funding cell based research is key driver for the global cell signaling market
Governments of various countries are promoting and supporting cell-based research activities such as cell signalling, single-cell analysis, and stem cell research. A large portion of the funding from governments is provided to academic research societies to promote cell-based research, which helps in the evaluation of diagnostic and therapeutic applications of various types of cells in the management of chronic and infectious diseases. By driving research into the application and end-user industries for cell analysis, the availability of support plays a significant role in aiding market growth.
Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=80206120
Market Segmentation in Depth:
By pathway, segmented into AMP-activated protein kinase (AMPK), Akt, ErbB/HER, Hedgehog (Hh), NF-êB, Janus kinase and signal transducer and activator of transcription (JAK/STAT), Notch, and other signaling pathways. The Akt pathway segment is estimated to account for the largest share of the cell signaling market.
On the basis of technology, segmented into enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), microscopy, flow cytometry, western blotting, mass spectrometry, and other technologies (immunofluorescence and immunoprecipitation). The microscopy segment is estimated to account for the largest share.
Based on application, segmented into research applications (stem cell, immunology, cancer, and other research applications), and medical applications. The research applications segment is estimated to account the largest share of cell signaling market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80206120
On the basis of region, the market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to account for the largest share of the cell signaling market. Growth in this regional segment is driven by the growth in geriatric population, rising incidence of chronic diseases, and improved life science research infrastructure in the region.
The key players in the market include Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Beckman Coulter, Inc. (U.S.) (a subsidiary of Danaher Corporation), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer Inc. (U.S.), QIAGEN N.V. (Netherlands), Cell Signaling Technology, Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.)
Merck KGaA (Germany) held the leading position in the cell signaling market in 2016. The company focuses on acquisitions as its key strategy to exploit growth opportunities in the market. For instance, in November 2015, Merck KGaA completed acquisition of Sigma-Aldrich Corporation (U.S.) for USD 17.00 billion. This acquisition helped Merck KGaA to expand its life science research product portfolio around the world.